- New alliance will crack down on adulterated products touting dietary supplement claims
- FDA releases annual 'Generic Drug Roundup'
- Senator to float bill to address drug shortages
- NACDS responds to report on integrity of pharmaceutical supply chain
- Merck's hepatitis C drug granted priority review by FDA
PISCATAWAY, N.J. — A company focused on developing niche generic and specialty pharmaceutical products has received regulatory approval from the Food and Drug Administration for its version of a psychiatric drug.
Innopharma said its abbreviated new drug application for olanzapine injection, a generic equivalent of Zyprexa injection. With this approval, Innopharma announced that it has entered an agreement with Sandoz, who will sell, market and distribute Innopharma's generic in the United States.
Innopharma joins several other drug makers that received FDA approval earlier this week to market their versions of Zyprexa and Zyprexa Zydus, which are designed to treat schizophrenia and bipolar disorder.